Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
Table 1
Comparison of eligible patients for DAPA-HF and EMPEROR-reduced, compared to patients receiving trial drug in respective trial.
Characteristic
Umeå cohort eligible for DAPA-HF ()
DAPA-HF population ()
Umeå cohort eligible for EMPEROR-reduced ()
EMPEROR-reduced population ()
value
value
Age-yr
79.0 (±10.0)
66.2 (±11)
<.001
80.3 (±9.8)
67.2 (±10.8)
<.001
Female sex-no. (%)
119 (33.8)
564 (23.8)
<.001
93 (34.7)
437 (23.5)
Body-mass index-kg/m2
26.4 (±4.9)
28.2 (±6.0)
<.001
26.3 (±4.8)
28.0 (±5.5)
<.001
Heart rate-beats/min
75.6 (±17.2)
71.5 (±11.8)
<.001
76.3 (±17.0)
71.0 (±11.7)
<.001
Systolic blood pressure-mmHg
124 (±18.2)
122 (±11.8)
.026
126 (±18.0)
123 (±15.9)
.002
Left ventricle ejection fraction-%
32.4 (±6.8)
31.2 (±6.7)
.002
30.1 (±6.7)
27.7 (±6.0)
<.001
Median NT-proBNP-ng/ml (IQR)
1943 (1138-3562)
1428 (857-2655)
2897 (1607-4872)
1887 (1077-3429)
eGFR-ml/min/1.73 m2
54.4 (±15.0)
66 (±19.6)
<.001
49.5 (±17.8)
61.8 (±21.7)
<.001
Rate of eGFR <60 ml/min/1.73 m2-no./total no. (%)
239/352 (67.9%)
962/2372 (40.6)
<.001
198/268 (73.9)
893/1862 (48.0)
<.001
Hospitalization for heart failure-no. (%)
182 (51.7)
1124 (47.4)
.14
175 (65.3)
Atrial fibrillation-no. (%)
198 (56.3)
916 (38.6)
<.001
142 (53.0)
664 (35.6)
<.001
Diabetes mellitus-no. (%)
74 (21.0)
993 (41.8)
<.001
70 (26.1)
927 (49.8)
<.001
Hypertension-no. (%)
222 (63.1)
n/a
182 (67.9)
1349 (72.4)
.15
Ischemic etiology-no. (%)
163 (46.3)
1316 (55.5)
.002
130 (48.5)
983 (52.8)
.22
Heart failure treatment
ACE-inhibitor or ARB-no. (%)
258 (73.3)
2007 (84.6)
<.001
195 (72.8)
1314 (70.5)
.50
ARNI-No. (%)
63 (17.9)
250 (10.5)
<.001
50 (18.7)
340 (18.3)
.94
MRA-no. (%)
213 (60.5)
1696 (71.5)
<.001
167 (62.3)
1306 (70.1)
.012
Beta blocker-no. (%)
322 (91.5)
2278 (96.0)
<.001
244 (91)
1765 (94.7)
.014
Diuretic-no. (%)
233 (66.2)
2216 (93.4)
<.001
204 (76.1)
n/a
Digitalis-No (%)
52 (14.8)
445 (18.8)
.084
36 (13.4)
n/a
ICD-no. (%)
47 (13.4)
622 (26.6)
<.001
38 (14.2)
578 (31.0)
<.001
CRT-no. (%)
53 (15.1)
190 (8.0)
<.001
46 (17.2)
220 (11.8)
.02
Number in parentheses is ±1 standard deviation; eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal pro-B-type natriuretic peptide; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor blocker and neprilysin inhibitor; MRA: mineral corticoid antagonist; ICD: implantable cardioverter-defibrillator; CRT: cardiac resynchronization therapy. BMI available for 333/352 patients. BMI available for 255/268 patients. DAPA-HF reports prior HF hospitalization, and EMPEROR-reduced reports hospitalizations in the last 12 months.